VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q64021961  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000338.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q64021961‏
024 ‎‡a  0000-0002-2291-1740‏ ‎‡2  orcid‏
024 ‎‡a  7403985361‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q64021961‏
100 0 ‎‡a  David Morgan‏ ‎‡9  nl‏ ‎‡9  es‏ ‎‡9  ast‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  ডেভিড মর্গান‏ ‎‡9  bn‏
400 0 ‎‡a  David Morgan‏ ‎‡c  researcher (ORCID 0000-0002-2291-1740)‏ ‎‡9  en‏
670 ‎‡a  Author's A comparison of late cosmetic results following two different radiotherapy techniques for treating basal cell carcinoma.‏
670 ‎‡a  Author's A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts‏
670 ‎‡a  Author's A vision to optimise the management of primary breast cancer in older women.‏
670 ‎‡a  Author's Addendum to BASOII Trial report‏
670 ‎‡a  Author's Biologic comparisons of partial breast irradiation schedules: In regard to Rosenstein et al. (Int J Radiat Oncol Biol Phys 2004;60:1391-1404)‏
670 ‎‡a  Author's Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts.‏
670 ‎‡a  Author's Boost or not‏
670 ‎‡a  Author's Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network‏
670 ‎‡a  Author's Breast conservation in ductal carcinoma in situ‏
670 ‎‡a  Author's Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?‏
670 ‎‡a  Author's Cancer-information seeking‏
670 ‎‡a  Author's Carcinoma of the larynx and hypopharynx in the elderly‏
670 ‎‡a  Author's Care of the older woman with primary breast cancer: a sign of the times?‏
670 ‎‡a  Author's Early results of radiotherapy for advanced laryngeal cancer using three small fractions per day‏
670 ‎‡a  Author's Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer‏
670 ‎‡a  Author's Incidence of clinically significant lymphoedema as a complication following surgery for primary operable breast cancer‏
670 ‎‡a  Author's Is local control necessarily an indicator of quality?‏
670 ‎‡a  Author's Leiomyosarcoma of the larynx‏
670 ‎‡a  Author's Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women‏
670 ‎‡a  Author's Locally advanced breast cancer: long-term results of a randomized trial comparing primary treatment with tamoxifen or radiotherapy in post-menopausal women‏
670 ‎‡a  Author's Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic.‏
670 ‎‡a  Author's Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre‏
670 ‎‡a  Author's Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial‏
670 ‎‡a  Author's Minimising carotid artery dose in the radiotherapy of early glottic cancer‏
670 ‎‡a  Author's Optimising the management of primary breast cancer in older women – A report of a multi-disciplinary study day‏
670 ‎‡a  Author's Pathological features of primary breast cancer in the elderly based on needle core biopsies—A large series from a single centre‏
670 ‎‡a  Author's Perspectives in breast cancer treatment: APBI and breast-conserving surgery. In regard to Moran et al and Smith et al‏
670 ‎‡a  Author's Postoperative radiotherapy following mastectomy for high-risk breast cancer. A randomised trial‏
670 ‎‡a  Author's Prophylactic cranial irradiation for small-cell lung cancer: long-term results‏
670 ‎‡a  Author's Radiotherapy as sole adjuvant treatment for older patients with low-risk breast cancer.‏
670 ‎‡a  Author's Radiotherapy in older women with low-risk breast cancer: why has practice not changed?‏
670 ‎‡a  Author's Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology‏
670 ‎‡a  Author's Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial‏
670 ‎‡a  Author's Radiotherapy plus chemotherapy for head and neck cancer‏
670 ‎‡a  Author's Redox protein expression predicts radiotherapeutic response in early-stage invasive breast cancer patients.‏
670 ‎‡a  Author's Safe selection criteria for breast conservation without radical excision in primary operable invasive breast cancer‏
670 ‎‡a  Author's Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and‏
670 ‎‡a  Author's Should radiotherapy be omitted in women age 70 years or older with early breast cancer?‏
670 ‎‡a  Author's Successful management of elderly breast cancer patients treated without radiotherapy.‏
670 ‎‡a  Author's Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999‏
670 ‎‡a  Author's The prediction of local or regional recurrence after simple mastectomy for operable breast cancer‏
670 ‎‡a  Author's The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: number or stage‏
670 ‎‡a  Author's The prognostic significance of lymphovascular invasion in invasive breast carcinoma‏
670 ‎‡a  Author's The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.‏
670 ‎‡a  Author's The use of a commercial remote desktop program in the delineation of target volumes in radiotherapy‏
670 ‎‡a  Author's Vascular endothelial growth factor expression predicts outcome after primary radiotherapy for head and neck squamous cell cancer.‏
909 ‎‡a  (orcid) 0000000222911740‏ ‎‡9  1‏
909 ‎‡a  (scopus) 7403985361‏ ‎‡9  1‏
919 ‎‡a  perspectivesinbreastcancertreatmentapbiandbreastconservingsurgeryinregardtomoranetalandsmithetal‏ ‎‡A  Perspectives in breast cancer treatment: APBI and breast-conserving surgery. In regard to Moran et al and Smith et al‏ ‎‡9  1‏
919 ‎‡a  postoperativeradiotherapyfollowingmastectomyforhighriskbreastcancerarandomisedtrial‏ ‎‡A  Postoperative radiotherapy following mastectomy for high-risk breast cancer. A randomised trial‏ ‎‡9  1‏
919 ‎‡a  prophylacticcranialirradiationforsmallcelllungcancerlongtermresults‏ ‎‡A  Prophylactic cranial irradiation for small-cell lung cancer: long-term results‏ ‎‡9  1‏
919 ‎‡a  radiotherapyassoleadjuvanttreatmentforolderpatientswithlowriskbreastcancer‏ ‎‡A  Radiotherapy as sole adjuvant treatment for older patients with low-risk breast cancer.‏ ‎‡9  1‏
919 ‎‡a  radiotherapyinolderwomenwithlowriskbreastcancerwhyhaspracticenotchanged‏ ‎‡A  Radiotherapy in older women with low-risk breast cancer: why has practice not changed?‏ ‎‡9  1‏
919 ‎‡a  radiotherapyortamoxifenafterconservingsurgeryforbreastcancersofexcellentprognosisbritishassociationofsurgicaloncology‏ ‎‡A  Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology‏ ‎‡9  1‏
919 ‎‡a  radiotherapyortamoxifenafterconservingsurgeryforbreastcancersofexcellentprognosisbritishassociationofsurgicaloncologybaso2trial‏ ‎‡A  Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial‏ ‎‡9  1‏
919 ‎‡a  radiotherapypluschemotherapyforheadandneckcancer‏ ‎‡A  Radiotherapy plus chemotherapy for head and neck cancer‏ ‎‡9  1‏
919 ‎‡a  redoxproteinexpressionpredictsradiotherapeuticresponseinearlystageinvasivebreastcancerpatients‏ ‎‡A  Redox protein expression predicts radiotherapeutic response in early-stage invasive breast cancer patients.‏ ‎‡9  1‏
919 ‎‡a  safeselectioncriteriaforbreastconservationwithoutradicalexcisioninprimaryoperableinvasivebreastcancer‏ ‎‡A  Safe selection criteria for breast conservation without radical excision in primary operable invasive breast cancer‏ ‎‡9  1‏
919 ‎‡a  vascularendothelialgrowthfactorexpressionpredictsoutcomeafterprimaryradiotherapyforheadandnecksquamouscellcancer‏ ‎‡A  Vascular endothelial growth factor expression predicts outcome after primary radiotherapy for head and neck squamous cell cancer.‏ ‎‡9  1‏
919 ‎‡a  useofacommercialremotedesktopprograminthedelineationoftargetvolumesinradiotherapy‏ ‎‡A  The use of a commercial remote desktop program in the delineation of target volumes in radiotherapy‏ ‎‡9  1‏
919 ‎‡a  ukstandardisationofbreastradiotherapystarttrialbofradiotherapyhypofractionationfortreatmentofearlybreastcancerarandomisedtrial‏ ‎‡A  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.‏ ‎‡9  1‏
919 ‎‡a  prognosticsignificanceoflymphovascularinvasionininvasivebreastcarcinoma‏ ‎‡A  The prognostic significance of lymphovascular invasion in invasive breast carcinoma‏ ‎‡9  1‏
919 ‎‡a  prognosticsignificanceofearlystagelymphnodepositivityinoperableinvasivebreastcarcinomanumberorstage‏ ‎‡A  The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: number or stage‏ ‎‡9  1‏
919 ‎‡a  predictionoflocalorregionalrecurrenceaftersimplemastectomyforoperablebreastcancer‏ ‎‡A  The prediction of local or regional recurrence after simple mastectomy for operable breast cancer‏ ‎‡9  1‏
919 ‎‡a  survivalofinvasivebreastcanceraccordingtothenottinghamprognosticindexincasesdiagnosedin1990‏ ‎‡A  Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999‏ ‎‡9  1‏
919 ‎‡a  successfulmanagementofelderlybreastcancerpatientstreatedwithoutradiotherapy‏ ‎‡A  Successful management of elderly breast cancer patients treated without radiotherapy.‏ ‎‡9  1‏
919 ‎‡a  shouldradiotherapybeomittedinwomenage70yearsorolderwithearlybreastcancer‏ ‎‡A  Should radiotherapy be omitted in women age 70 years or older with early breast cancer?‏ ‎‡9  1‏
919 ‎‡a  shortenedirradiationschemecontinuousinfusionof5fluorouracilandfractionationofmitomycin100inlocallyadvancedanalcarcinomasresultsofaphase2studyoftheeuropeanorganizationforresearchandtreatmentofcancerradiotherapyand‏ ‎‡A  Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and‏ ‎‡9  1‏
919 ‎‡a  comparisonoflatecosmeticresultsfollowing2differentradiotherapytechniquesfortreatingbasalcellcarcinoma‏ ‎‡A  A comparison of late cosmetic results following two different radiotherapy techniques for treating basal cell carcinoma.‏ ‎‡9  1‏
919 ‎‡a  studyofductalversusnonductalinvasivebreastcarcinomasinolderwomenlongtermclinicaloutcomeandcomparisonwiththeiryoungercounterparts‏ ‎‡A  A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts‏ ‎‡9  1‏
919 ‎‡a  visiontooptimisethemanagementofprimarybreastcancerinolderwomen‏ ‎‡A  A vision to optimise the management of primary breast cancer in older women.‏ ‎‡9  1‏
919 ‎‡a  addendumtobasoiitrialreport‏ ‎‡A  Addendum to BASOII Trial report‏ ‎‡9  1‏
919 ‎‡a  biologiccomparisonsofpartialbreastirradiationschedulesinregardtorosensteinetalintjradiatoncolbiolphys2004601391‏ ‎‡A  Biologic comparisons of partial breast irradiation schedules: In regard to Rosenstein et al. (Int J Radiat Oncol Biol Phys 2004;60:1391-1404)‏ ‎‡9  1‏
919 ‎‡a  biologicalcharacteristicsandclinicaloutcomeoftriplenegativeprimarybreastcancerinolderwomencomparisonwiththeiryoungercounterparts‏ ‎‡A  Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts.‏ ‎‡9  1‏
919 ‎‡a  boostornot‏ ‎‡A  Boost or not‏ ‎‡9  1‏
919 ‎‡a  boostradiotherapyinyoungwomenwithductalcarcinomainsituamulticentreretrospectivestudyoftherarecancernetwork‏ ‎‡A  Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network‏ ‎‡9  1‏
919 ‎‡a  breastconservationinductalcarcinomainsitu‏ ‎‡A  Breast conservation in ductal carcinoma in situ‏ ‎‡9  1‏
919 ‎‡a  breastconservationinductalcarcinomainsitudciswhatdefinesoptimalmargins‏ ‎‡A  Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?‏ ‎‡9  1‏
919 ‎‡a  cancerinformationseeking‏ ‎‡A  Cancer-information seeking‏ ‎‡9  1‏
919 ‎‡a  carcinomaofthelarynxandhypopharynxintheelderly‏ ‎‡A  Carcinoma of the larynx and hypopharynx in the elderly‏ ‎‡9  1‏
919 ‎‡a  careoftheolderwomanwithprimarybreastcancerasignofthetimes‏ ‎‡A  Care of the older woman with primary breast cancer: a sign of the times?‏ ‎‡9  1‏
919 ‎‡a  earlyresultsofradiotherapyforadvancedlaryngealcancerusing3smallfractionsperday‏ ‎‡A  Early results of radiotherapy for advanced laryngeal cancer using three small fractions per day‏ ‎‡9  1‏
919 ‎‡a  expressionofthioredoxinsystemandrelatedperoxiredoxinproteinsisassociatedwithclinicaloutcomeinradiotherapytreatedearlystagebreastcancer‏ ‎‡A  Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer‏ ‎‡9  1‏
919 ‎‡a  incidenceofclinicallysignificantlymphoedemaasacomplicationfollowingsurgeryforprimaryoperablebreastcancer‏ ‎‡A  Incidence of clinically significant lymphoedema as a complication following surgery for primary operable breast cancer‏ ‎‡9  1‏
919 ‎‡a  islocalcontrolnecessarilyanindicatorofquality‏ ‎‡A  Is local control necessarily an indicator of quality?‏ ‎‡9  1‏
919 ‎‡a  leiomyosarcomaofthelarynx‏ ‎‡A  Leiomyosarcoma of the larynx‏ ‎‡9  1‏
919 ‎‡a  liverkinaseb1apotentialtherapeutictargetinhormonesensitivebreastcancerinolderwomen‏ ‎‡A  Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women‏ ‎‡9  1‏
919 ‎‡a  locallyadvancedbreastcancerlongtermresultsofarandomizedtrialcomparingprimarytreatmentwithtamoxifenorradiotherapyinpostmenopausalwomen‏ ‎‡A  Locally advanced breast cancer: long-term results of a randomized trial comparing primary treatment with tamoxifen or radiotherapy in post-menopausal women‏ ‎‡9  1‏
919 ‎‡a  longterm37yearsclinicaloutcomeofolderwomenwithearlyoperableprimarybreastcancermanagedinadedicatedclinic‏ ‎‡A  Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic.‏ ‎‡9  1‏
919 ‎‡a  longtermclinicaloutcomeofoestrogenreceptorpositiveoperableprimarybreastcancerinolderwomenalargeseriesfromasinglecentre‏ ‎‡A  Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre‏ ‎‡9  1‏
919 ‎‡a  maintenancechemotherapyforanaplasticsmallcellcarcinomaofthebronchusarandomisedcontrolledtrial‏ ‎‡A  Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial‏ ‎‡9  1‏
919 ‎‡a  minimisingcarotidarterydoseintheradiotherapyofearlyglotticcancer‏ ‎‡A  Minimising carotid artery dose in the radiotherapy of early glottic cancer‏ ‎‡9  1‏
919 ‎‡a  optimisingthemanagementofprimarybreastcancerinolderwomenareportofamultidisciplinarystudyday‏ ‎‡A  Optimising the management of primary breast cancer in older women – A report of a multi-disciplinary study day‏ ‎‡9  1‏
919 ‎‡a  pathologicalfeaturesofprimarybreastcancerintheelderlybasedonneedlecorebiopsiesalargeseriesfromasinglecentre‏ ‎‡A  Pathological features of primary breast cancer in the elderly based on needle core biopsies—A large series from a single centre‏ ‎‡9  1‏
943 ‎‡a  199x‏ ‎‡A  1999‏ ‎‡9  1‏
943 ‎‡a  140x‏ ‎‡A  1404‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  ISNI|0000000048845716‏
996 ‎‡2  LC|no2010132823‏
996 ‎‡2  SUDOC|250757745‏
996 ‎‡2  BIBSYS|2121396‏
996 ‎‡2  DNB|133648826‏
996 ‎‡2  ISNI|0000000110827034‏
996 ‎‡2  LC|no2007150856‏
996 ‎‡2  LC|no2008025933‏
996 ‎‡2  LC|n 90604941‏
996 ‎‡2  DNB|131815040‏
996 ‎‡2  BNF|16206552‏
996 ‎‡2  SUDOC|030351987‏
996 ‎‡2  J9U|987007366445205171‏
996 ‎‡2  BNF|17864412‏
996 ‎‡2  SUDOC|032205430‏
996 ‎‡2  NUKAT|n 2011068966‏
996 ‎‡2  DNB|1043764569‏
996 ‎‡2  LC|nb2004034645‏
996 ‎‡2  LC|no 94004053‏
996 ‎‡2  BIBSYS|90600579‏
996 ‎‡2  LC|nb2018009304‏
996 ‎‡2  ISNI|0000000039453681‏
996 ‎‡2  NII|DA07115033‏
996 ‎‡2  BNF|16549259‏
996 ‎‡2  CAOONL|ncf10135472‏
996 ‎‡2  BIBSYS|90083562‏
996 ‎‡2  ISNI|0000000356199736‏
996 ‎‡2  PTBNP|1460356‏
996 ‎‡2  LC|no2009188265‏
996 ‎‡2  LC|n 2004119895‏
996 ‎‡2  LC|n 2002134488‏
996 ‎‡2  NDL|00450498‏
996 ‎‡2  SUDOC|193015552‏
996 ‎‡2  ISNI|0000000035235775‏
996 ‎‡2  LC|no2011014781‏
996 ‎‡2  LC|n 89600117‏
996 ‎‡2  LC|no2015128227‏
996 ‎‡2  DBC|87097969614299‏
996 ‎‡2  ISNI|0000000035260700‏
996 ‎‡2  NTA|079385583‏
996 ‎‡2  LC|nb2022018020‏
996 ‎‡2  SUDOC|188198563‏
996 ‎‡2  ISNI|0000000053023653‏
996 ‎‡2  BNC|981058510140906706‏
996 ‎‡2  LC|n 2015000625‏
996 ‎‡2  RERO|A017694637‏
996 ‎‡2  SUDOC|242510272‏
996 ‎‡2  ISNI|000000007637080X‏
996 ‎‡2  LC|n 99016211‏
996 ‎‡2  SUDOC|115934626‏
996 ‎‡2  CAOONL|ncf11874077‏
996 ‎‡2  NDL|01129415‏
996 ‎‡2  DNB|124546583X‏
996 ‎‡2  BIBSYS|97039904‏
996 ‎‡2  LC|no2020022145‏
996 ‎‡2  LC|n 88127457‏
996 ‎‡2  LC|nb2012029325‏
996 ‎‡2  NKC|xx0000402‏
996 ‎‡2  ISNI|0000000107317260‏
996 ‎‡2  BNF|12328156‏
996 ‎‡2  ISNI|0000000075322718‏
996 ‎‡2  PLWABN|9810594141305606‏
996 ‎‡2  SZ|1143154045‏
996 ‎‡2  BNCHL|10000000000000000803782‏
996 ‎‡2  RERO|A024416974‏
996 ‎‡2  CAOONL|ncf12097651‏
996 ‎‡2  ISNI|0000000083468880‏
996 ‎‡2  LC|nb2008017207‏
996 ‎‡2  ISNI|000000002152447X‏
996 ‎‡2  NKC|xx0001710‏
996 ‎‡2  CAOONL|ncf11275302‏
996 ‎‡2  NSK|000705759‏
996 ‎‡2  SUDOC|139049703‏
996 ‎‡2  ISNI|0000000039058964‏
996 ‎‡2  DNB|1206005238‏
996 ‎‡2  CAOONL|ncf10334921‏
996 ‎‡2  SUDOC|077002970‏
996 ‎‡2  DNB|143567748‏
996 ‎‡2  DNB|1133310060‏
996 ‎‡2  ISNI|0000000037342320‏
996 ‎‡2  CAOONL|ncf10124963‏
996 ‎‡2  ISNI|0000000034439266‏
996 ‎‡2  LC|n 2015001169‏
996 ‎‡2  LC|no2024095755‏
996 ‎‡2  ISNI|0000000051080785‏
996 ‎‡2  SUDOC|030542677‏
996 ‎‡2  LC|n 2019008619‏
996 ‎‡2  RERO|A003609429‏
996 ‎‡2  DNB|1089127057‏
996 ‎‡2  NTA|214118088‏
996 ‎‡2  LC|no2019050555‏
996 ‎‡2  J9U|987007438426605171‏
996 ‎‡2  NKC|mub2016910316‏
996 ‎‡2  SUDOC|232653623‏
996 ‎‡2  PLWABN|9810626663405606‏
996 ‎‡2  SUDOC|146214439‏
996 ‎‡2  SUDOC|074654551‏
996 ‎‡2  NTA|070303037‏
996 ‎‡2  ISNI|0000000499087862‏
996 ‎‡2  NYNYRILM|250929‏
996 ‎‡2  J9U|987007453437605171‏
996 ‎‡2  LC|n 95067377‏
996 ‎‡2  BNF|11916848‏
996 ‎‡2  CAOONL|ncf10533246‏
996 ‎‡2  ISNI|0000000073429159‏
996 ‎‡2  LC|n 94117258‏
996 ‎‡2  J9U|987007605722305171‏
996 ‎‡2  NTA|074733346‏
996 ‎‡2  ISNI|0000000367566298‏
996 ‎‡2  LIH|LNB:8L_t_;=B_e_‏
996 ‎‡2  J9U|987007323284705171‏
996 ‎‡2  NTA|074021710‏
996 ‎‡2  ISNI|0000000080892264‏
996 ‎‡2  J9U|987007434943805171‏
996 ‎‡2  DBC|87097969614302‏
996 ‎‡2  NTA|390738867‏
996 ‎‡2  LC|nb2004009148‏
996 ‎‡2  LC|n 2001093234‏
996 ‎‡2  LC|no2018149501‏
996 ‎‡2  RERO|A006003101‏
996 ‎‡2  ISNI|0000000076301345‏
996 ‎‡2  BNF|17806390‏
996 ‎‡2  NTA|338133291‏
996 ‎‡2  LC|n 88143308‏
996 ‎‡2  DNB|1263708986‏
996 ‎‡2  LC|n 92028316‏
996 ‎‡2  LC|n 87930003‏
996 ‎‡2  ISNI|0000000083521688‏
996 ‎‡2  NSK|000518149‏
996 ‎‡2  BNF|12178492‏
996 ‎‡2  ISNI|0000000114953775‏
996 ‎‡2  ERRR|11899153‏
996 ‎‡2  RERO|A016759330‏
996 ‎‡2  LC|no2011072616‏
996 ‎‡2  BNF|12374308‏
996 ‎‡2  LC|nb2010026134‏
996 ‎‡2  ISNI|0000000444493935‏
996 ‎‡2  DNB|1263707904‏
996 ‎‡2  J9U|987007448306605171‏
996 ‎‡2  NLA|000036018058‏
996 ‎‡2  LC|n 50005819‏
996 ‎‡2  LC|n 50005818‏
996 ‎‡2  BAV|495_144594‏
996 ‎‡2  ISNI|0000000074952638‏
996 ‎‡2  NTA|429410816‏
996 ‎‡2  N6I|vtls002040557‏
996 ‎‡2  LC|n 86036311‏
996 ‎‡2  BIBSYS|7042565‏
996 ‎‡2  J9U|987007428315005171‏
996 ‎‡2  NUKAT|n 2008109346‏
996 ‎‡2  ISNI|0000000089763055‏
996 ‎‡2  ISNI|0000000094126552‏
996 ‎‡2  LC|n 2014032312‏
996 ‎‡2  LC|no2016169954‏
996 ‎‡2  SELIBR|mxkqsvz1k7mx3k3c‏
996 ‎‡2  LC|no2016079412‏
996 ‎‡2  LC|nb2018024611‏
996 ‎‡2  NII|DA13138463‏
996 ‎‡2  ISNI|0000000028247428‏
996 ‎‡2  PLWABN|9810815381505606‏
996 ‎‡2  ISNI|0000000495813847‏
996 ‎‡2  LC|nb 97047529‏
996 ‎‡2  SIMACOB|79391075‏
996 ‎‡2  DNB|1151132519‏
996 ‎‡2  ISNI|000000039954136X‏
996 ‎‡2  LC|n 86025908‏
996 ‎‡2  NUKAT|n 01017402‏
996 ‎‡2  DNB|1137491035‏
996 ‎‡2  RERO|A012351563‏
996 ‎‡2  LC|n 2002153772‏
996 ‎‡2  NII|DA02582880‏
996 ‎‡2  LIH|LNB:2WE;=_w_3‏
996 ‎‡2  PLWABN|9811269511105606‏
996 ‎‡2  NTA|071184449‏
996 ‎‡2  DBC|87097991618532‏
996 ‎‡2  LC|nr2007003883‏
996 ‎‡2  RERO|A016759416‏
996 ‎‡2  J9U|987007463643705171‏
996 ‎‡2  NII|DA03783629‏
996 ‎‡2  LNB|LNC10-000175408‏
996 ‎‡2  NTA|242573797‏
996 ‎‡2  PLWABN|9813156748605606‏
996 ‎‡2  LIH|LNB:7A0;=_e__p_‏
996 ‎‡2  NUKAT|n 2006107350‏
996 ‎‡2  DNB|118541049X‏
996 ‎‡2  ISNI|0000000032188205‏
996 ‎‡2  LC|nr 93026753‏
996 ‎‡2  J9U|987007449820005171‏
996 ‎‡2  BIBSYS|90273427‏
996 ‎‡2  BIBSYS|90273426‏
996 ‎‡2  ISNI|0000000496204218‏
996 ‎‡2  LC|n 85060802‏
996 ‎‡2  LC|n 82133157‏
996 ‎‡2  DNB|1048368653‏
996 ‎‡2  ISNI|0000000078365326‏
996 ‎‡2  CAOONL|ncf11452919‏
996 ‎‡2  ISNI|0000000072781070‏
996 ‎‡2  LC|n 2019067927‏
996 ‎‡2  NTA|147548012‏
996 ‎‡2  LC|no 97031088‏
996 ‎‡2  SUDOC|226378349‏
996 ‎‡2  ISNI|0000000427448067‏
996 ‎‡2  LC|n 77003443‏
996 ‎‡2  LC|n 85077610‏
996 ‎‡2  LC|no 89009300‏
996 ‎‡2  BNF|16664041‏
996 ‎‡2  NUKAT|n 2003063537‏
996 ‎‡2  LIH|LNB:B6_m__p_;=B1‏
996 ‎‡2  NTA|068541759‏
996 ‎‡2  LC|n 78028708‏
996 ‎‡2  LIH|LNB:H_e__f_;=B_j_‏
996 ‎‡2  LC|n 2015000632‏
996 ‎‡2  NUKAT|n 2005111043‏
996 ‎‡2  LC|n 2015000637‏
996 ‎‡2  ISNI|0000000365824302‏
996 ‎‡2  BNF|17767007‏
996 ‎‡2  NUKAT|n 2017243179‏
996 ‎‡2  LC|n 84055800‏
996 ‎‡2  ISNI|0000000501449309‏
996 ‎‡2  NII|DA07584602‏
996 ‎‡2  NII|DA03796813‏
996 ‎‡2  ISNI|0000000444548000‏
996 ‎‡2  J9U|987007592400705171‏
996 ‎‡2  BNF|15033466‏
996 ‎‡2  ISNI|0000000108164999‏
996 ‎‡2  NII|DA00447873‏
996 ‎‡2  LC|no2012160903‏
996 ‎‡2  ISNI|0000000026222534‏
996 ‎‡2  DNB|1147172870‏
996 ‎‡2  CAOONL|ncf11551158‏
996 ‎‡2  SUDOC|078672376‏
996 ‎‡2  NTA|355538202‏
996 ‎‡2  LC|no2015155711‏
996 ‎‡2  LIH|LNB:DD_i_S;=B_a_‏
996 ‎‡2  NTA|129722952‏
996 ‎‡2  J9U|987007328902705171‏
996 ‎‡2  BIBSYS|90329374‏
996 ‎‡2  LC|n 97802794‏
996 ‎‡2  LC|no2012021618‏
996 ‎‡2  LC|no 93021160‏
996 ‎‡2  NKC|stk2009477357‏
996 ‎‡2  LC|n 2010038825‏
996 ‎‡2  J9U|987007364765905171‏
996 ‎‡2  ISNI|0000000031810808‏
996 ‎‡2  CAOONL|ncf11194405‏
996 ‎‡2  ISNI|0000000030486292‏
996 ‎‡2  LC|n 81035903‏
996 ‎‡2  DNB|1158406169‏
996 ‎‡2  LC|nr 89000129‏
996 ‎‡2  DNB|128700173‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏
998 ‎‡a  Morgan, David‏ ‎‡2  ISNI|0000000078365326‏ ‎‡3  exact name‏
998 ‎‡a  Morgan, David‏ ‎‡2  ISNI|0000000078365326‏ ‎‡3  exact name‏
998 ‎‡a  David Morgan‏ ‎‡2  ISNI|0000000078365326‏ ‎‡3  exact name‏
998 ‎‡a  Morgan, David W.‏ ‎‡2  ISNI|0000000078365326‏ ‎‡3  exact name‏
998 ‎‡a  David, Morgan‏ ‎‡2  SUDOC|076400255‏ ‎‡3  exact name‏